{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:15:31Z","timestamp":1759331731864},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o de apoio \u00e0 pesquisa do DF (FAP-DF), FAHUB, CAPES CNPQ and Funda\u00e7\u00e3o de Ensino e Pesquisa em Ci\u00eancias da Sa\u00fade (FEPECS).","award":["0"],"award-info":[{"award-number":["0"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Considering the potential of p16 as a marker for diagnosis, prognosis and therapeutic response, the aim of this study was to assess its presence, via immunocytochemistry, in metastatic carcinoma of different primary sites and histological types obtained from effusions and peritoneal washings. A total of 118 samples including 85 of metastatic carcinoma and 33 samples of benign effusion\/peritoneal washing were prepared by the plasma\/thromboplastin method. Immunocytochemistry reactions were performed on cell block sections using antibodies against p16, claudin-4, MOC-31, calretinin, HBME and CD68.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>P16 overexpression was observed in 88.23% of all carcinoma samples. All cervix adenocarcinoma samples showed p16 overexpression. Overexpression in adenocarcinomas of ovary, lung and breast was observed in 93.75, 93.10 and 75% of the samples, respectively. Overexpression was observed in all different histological types analyzed: small cell carcinoma (lung), squamous cell carcinoma (cervical) and urothelial carcinoma (bladder). The specificity of p16 for carcinoma detection was of 96.96%.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Overexpression of p16 was observed in most metastatic carcinoma, from different primary sites and histological types, obtained from effusions and peritoneal washings. Due to its high frequency of overexpression in metastatic carcinoma, p16 may play a possible role in tumor progression and it may be considered as a complementary diagnostic marker depending on histological type and primary site of carcinoma.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-6670-5","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T04:49:42Z","timestamp":1584420582000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["P16 as a marker of carcinoma in effusions and peritoneal washing"],"prefix":"10.1186","volume":"20","author":[{"given":"Fabiana Pirani","family":"Carneiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rivad\u00e1vio Fernandes","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Vasconcelos Carneiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tercia Maria Mendes Lousa","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonora Maciel","family":"de Souza Vianna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo Henrique Soares","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andersen Charles","family":"Daros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela","family":"Peres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma Aparecida Souza","family":"Kuckelhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Barretto","family":"Motoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"6670_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1006\/excr.1997.3824","volume":"237","author":"M Serrano","year":"1997","unstructured":"Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res. 1997;237:7\u201313.","journal-title":"Exp Cell Res"},{"key":"6670_CR2","first-page":"24972503","volume":"10","author":"AK Witkiewicz","year":"2011","unstructured":"Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle. 2011;10:24972503.","journal-title":"Cell Cycle"},{"key":"6670_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.humpath.2015.12.021","volume":"51","author":"A Mahajan","year":"2016","unstructured":"Mahajan A. Practical issues in the application of p16 immunohistochemistry in diagnostic pathology. Hum Pathol. 2016;51:64\u201374.","journal-title":"Hum Pathol"},{"issue":"11","key":"6670_CR4","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.humpath.2015.07.012","volume":"46","author":"SY Chang","year":"2015","unstructured":"Chang SY, Keeney M, Law M, Donovan J, Aubry MC, Garcia J. Detection of human papillomavirus in non-small cell carcinoma of the lung. Hum Pathol. 2015;46(11):1592\u20137.","journal-title":"Hum Pathol"},{"key":"6670_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.anndiagpath.2017.11.008","volume":"33","author":"M \u0160vajdler","year":"2018","unstructured":"\u0160vajdler M, Mezencev R, Ondi\u010d O, \u0160a\u0161kov\u00e1 B, Muken\u0161n\u00e1bl P, Michal M. P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens. Ann Diagn Pathol. 2018;33:23\u20139.","journal-title":"Ann Diagn Pathol"},{"key":"6670_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/PAS.0b013e31817f9790","volume":"33","author":"AP Subhawong","year":"2009","unstructured":"Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, et al. Most basal-like breast carcinomas demonstrate the same Rb\u2212\/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol. 2009;33:163\u201375.","journal-title":"Am J Surg Pathol"},{"key":"6670_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1365-2559.2007.02682.x","volume":"50","author":"CJ O\u2019Neill","year":"2007","unstructured":"O\u2019Neill CJ, McBride HA, Connolly LE, Deavers MT, Malpica A, McCluggage WG. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology. 2007;50:773\u20139.","journal-title":"Histopathology"},{"key":"6670_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/PGP.0b013e318182c2d2","volume":"28","author":"V Phillips","year":"2009","unstructured":"Phillips V, Kelly P, McCluggage WG. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int J Gynecol Pathol. 2009;28:179\u201386.","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"6670_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/his.12948","volume":"69","author":"R Pare","year":"2016","unstructured":"Pare R, Shin JS, Lee CS. Increased expression of senescence markers p14(ARF) and p16(INK4a) in breast cancer is associated with an increased risk of disease recurrence and poor survival outcome. Histopathology. 2016;69(3):479\u201391.","journal-title":"Histopathology"},{"issue":"2","key":"6670_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.lungcan.2011.04.019","volume":"74","author":"J Tong","year":"2011","unstructured":"Tong J, Sun X, Cheng H, Zhao D, Ma J, Zhen Q, Cao Y, Zhu H, Bai J. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Lung Cancer. 2011;74(2):155\u201363.","journal-title":"Lung Cancer"},{"issue":"4","key":"6670_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/cjp2.109","volume":"4","author":"PF Rambau","year":"2018","unstructured":"Rambau PF, et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an ovarian tumor tissue analysis consortium study. J Pathol Clin Res. 2018;4(4):250\u201361.","journal-title":"J Pathol Clin Res"},{"issue":"18","key":"6670_CR12","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1158\/1078-0432.CCR-12-0903","volume":"18","author":"AK Witkiewicz","year":"2012","unstructured":"Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G, Knudsen ES. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2012;18(18):5110\u201322.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6670_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.suronc.2017.09.003","volume":"26","author":"Y Li","year":"2017","unstructured":"Li Y, Huang HC, Chen LQ, Xu LY, Li EM, Zhang JJ. Predictive biomarkers for response of esophageal cancer to chemo (radio)therapy: a systematic review and meta-analysis. Surg Oncol. 2017;26(4):460\u201372.","journal-title":"Surg Oncol"},{"key":"6670_CR14","first-page":"2019","volume":"18","author":"FP Carneiro","year":"2019","unstructured":"Carneiro FP, Junqueira MIM, Carneiro MV, Oliveira IA, Soares AC, Haar NV, Takano GHS, Vianna LMS, Caldas GC, Vieria DLM, Frutuoso LL, Brito LMR, Siqueira RVM, Parente AM, Castro TMML, Peres I, Mendes LMS, Borges TKS, Ferreira VM, Motoyama AB. Anti-EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash. Oncol Lett. 2019;18:2019\u201324.","journal-title":"Oncol Lett"},{"key":"6670_CR15","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(00)03312-2","volume":"356","author":"G Gastl","year":"2000","unstructured":"Gastl G, Spizzo G, Obrist P, et al. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet. 2000;356:1981\u20132.","journal-title":"Lancet"},{"issue":"3","key":"6670_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ctrv.2008.10.005","volume":"35","author":"I Tsoumpou","year":"2009","unstructured":"Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, Malamou-Mitsi V, Paraskevaidis E. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 2009;35(3):210\u201320.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"6670_CR17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1309\/AJCPUXLP7XD8OQYY","volume":"144","author":"LK Clinton","year":"2015","unstructured":"Clinton LK, Miyazaki K, Ayabe A, Davis J, Tauchi-Nishi P, Shimizu D. The LAST guidelines in clinical practice: implementing recommendations for p16 use. Am J Clin Pathol. 2015;144(6):844\u20139.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"6670_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/dc.23476","volume":"44","author":"T Oda","year":"2016","unstructured":"Oda T, Ogata S, Kawaguchi S, Minabe S, Dokyu M, Takahashi H, Kumazawa F, Shimazaki H, Takano M, Hase K, Ozeki Y, Kanoh S, Nakanishi K. Immunocytochemical utility of claudin-4 versus those of Ber-EP4 and MOC-31 in effusion cytology. Diagn Cytopathol. 2016;44(6):499\u2013504.","journal-title":"Diagn Cytopathol"},{"issue":"4","key":"6670_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cncy.21392","volume":"122","author":"VY Jo","year":"2014","unstructured":"Jo VY, Cibas ES, Pinkus GS. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2014;122(4):299\u2013306.","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"6670_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/dc.10039","volume":"26","author":"PA Fetsch","year":"2002","unstructured":"Fetsch PA, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol. 2002;26(1):61\u20136.","journal-title":"Diagn Cytopathol"},{"issue":"10","key":"6670_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/dc.20713","volume":"35","author":"K Nigro","year":"2007","unstructured":"Nigro K, Tynski Z, Wasman J, Abdul-Karim F, Wang N. Comparison of cell block preparation methods for nongynecologic ThinPrep specimens. Diagn Cytopathol. 2007;35(10):640\u20133.","journal-title":"Diagn Cytopathol"},{"issue":"3","key":"6670_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.lungcan.2012.11.018","volume":"79","author":"N Yanagawa","year":"2013","unstructured":"Yanagawa N, Wang A, Kohler D, Santos Gda C, Sykes J, Xu J, Pintilie M, Tsao MS. Human papilloma virus genome is rare in north American non-small cell lung carcinoma patients. Lung Cancer. 2013;79(3):215\u201320.","journal-title":"Lung Cancer"},{"issue":"10","key":"6670_CR23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/cncy.21462","volume":"122","author":"E Piaton","year":"2014","unstructured":"Piaton E, Casalegno JS, Advenier AS, Decaussin-Petrucci M, Mege-Lechevallier F, Ruffion A, Mekki Y. p16(INK4a) overexpression is not linked to oncogenic human papillomaviruses in patients with high-grade urothelial cancer cells. Cancer Cytopathol. 2014;122(10):760\u20139.","journal-title":"Cancer Cytopathol"},{"issue":"9","key":"6670_CR24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/dc.23501","volume":"44","author":"K Nabeshima","year":"2016","unstructured":"Nabeshima K, Matsumoto S, Hamasaki M, Hida T, Kamei T, Hiroshima K, Tsujimura T, Kawahara K. Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations. Diagn Cytopathol. 2016;44(9):774\u201380.","journal-title":"Diagn Cytopathol"},{"issue":"7","key":"6670_CR25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","volume":"39","author":"BS Sheffield","year":"2015","unstructured":"Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM, Churg A. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39(7):977\u201382.","journal-title":"Am J Surg Pathol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6670-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6670-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6670-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:24:17Z","timestamp":1615940657000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6670-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6670"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6670-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"13 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics in Research Committee of Brasilia University, Brazil. CAAE: 37194114.4.0000.5553. All subjects provided written consent to participate in the study. The study abides to the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u2018Not applicable\u2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}